NASDAQ:PTEPolarityte Stock Price, Forecast & News

$0.89

+0.02 (+2.30 %)

(As of 05/25/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.83

Now: $0.89▼

$0.90

50-Day Range

$0.82

MA: $0.97▼

$1.15

52-Week Range

$0.78

Now: $0.89▼

$6.90

Volume232,385 shs

Average Volume534,900 shs

Market Capitalization$34.23 million

P/E RatioN/A

Dividend YieldN/A

Beta1.72

PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Polarityte has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.40, Polarityte has a potential upside of 506.8% from its current price of $0.89.
Amount of Analyst Coverage
Polarityte has only been the subject of 4 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Polarityte has received 122 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Polarityte has received 105 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Polarityte has received 53.74% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Polarityte and other stocks. Vote “Outperform” if you believe PTE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PTE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Polarityte does not currently pay a dividend.
Dividend Growth
Polarityte does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Polarityte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $52,321.00 in company stock.
Percentage Held by Insiders
Only 8.38% of the stock of Polarityte is held by insiders.
Percentage Held by Institutions
Only 27.34% of the stock of Polarityte is held by institutions.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Polarityte are expected to grow in the coming year, from ($1.58) to ($1.01) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Polarityte is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Polarityte is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Polarityte has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.45 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:PTE

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.polarityte.com

Phone385-237-2279

Debt

Debt-to-Equity Ratio0.06

Current Ratio3.70

Quick Ratio3.68

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$5.65 million

Price / Sales6.06

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.42 per share

Price / Book0.63

Profitability

EPS (Most Recent Fiscal Year)($3.70)

Net Income$-92,490,000.00

Net Margins-1,561.72%

Return on Equity-157.30%

Return on Assets-116.60%

Miscellaneous

Employees153

Outstanding Shares38,464,000

Market Cap$34.23 million

Next Earnings DateN/A

OptionableOptionable

Receive PTE News and Ratings via Email

Sign-up to receive the latest news and ratings for PTE and its competitors with MarketBeat's FREE daily newsletter.

Polarityte (NASDAQ:PTE) Frequently Asked Questions

How has Polarityte's stock been impacted by COVID-19 (Coronavirus)?

Polarityte's stock was trading at $1.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PTE shares have decreased by 16.8% and is now trading at $0.8899. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Polarityte?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Polarityte in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Polarityte.

How were Polarityte's earnings last quarter?

Polarityte Inc (NASDAQ:PTE) announced its earnings results on Monday, May, 11th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.18. The business had revenue of $0.93 million for the quarter, compared to the consensus estimate of $1.27 million. Polarityte had a negative net margin of 1,561.72% and a negative return on equity of 157.30%. During the same quarter last year, the business earned ($1.18) EPS. View Polarityte's earnings history.

What price target have analysts set for PTE?

5 analysts have issued 1-year price targets for Polarityte's stock. Their forecasts range from $3.00 to $8.00. On average, they expect Polarityte's share price to reach $5.40 in the next year. This suggests a possible upside of 506.8% from the stock's current price. View analysts' price targets for Polarityte.

Has Polarityte been receiving favorable news coverage?

News stories about PTE stock have trended somewhat positive on Monday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Polarityte earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutPolarityte.

Are investors shorting Polarityte?

Polarityte saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 3,090,000 shares, a decrease of 6.4% from the March 31st total of 3,300,000 shares. Based on an average daily volume of 563,600 shares, the days-to-cover ratio is currently 5.5 days. Approximately 13.4% of the shares of the stock are short sold. View Polarityte's Current Options Chain.

Who are some of Polarityte's key competitors?

Some companies that are related to Polarityte include Gamida Cell (GMDA), Applied Genetic Technologies (AGTC), Champions Oncology (CSBR), Organovo (ONVO), Windtree Therapeutics (WINT), Neon Therapeutics (NTGN), Genocea Biosciences (GNCA), AIM ImmunoTech (AIM), Outlook Therapeutics (OTLK), INmune Bio (INMB), Idera Pharmaceuticals (IDRA), Microbot Medical (MBOT), Allena Pharmaceuticals (ALNA), aTyr Pharma (LIFE) and Acorda Therapeutics (ACOR). View all competitors.

What other stocks do shareholders of Polarityte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Polarityte investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), Outlook Therapeutics (OTLK), Unum Therapeutics (UMRX), BioNano Genomics (BNGO), Seanergy Maritime (SHIP), Ekso Bionics (EKSO), Matinas BioPharma (MTNB), OrganiGram (OGI) and Titan Pharmaceuticals (TTNP).

Who are Polarityte's key executives?

Polarityte's management team includes the following people:

Mr. David B. Seaburg, Chief Exec. Officer (Age 50, Pay $7.5k)
Dr. Edward Winslow Swanson, Chief Translational Medicine Officer & Co-Founder (Age 35, Pay $400k)
Mr. Paul Elliot Mann, Exec. Officer
Mr. Richard Hague, Pres & COO (Age 60)
Mr. Jacob Alexander Patterson, Interim Chief Financial Officer

What is Polarityte's stock symbol?

Polarityte trades on the NASDAQ under the ticker symbol "PTE."

Who are Polarityte's major shareholders?

Polarityte's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (3.30%), Sabby Management LLC (0.91%), State Street Corp (0.82%), Geode Capital Management LLC (0.81%), Advisor Group Holdings Inc. (0.50%) and Levin Capital Strategies L.P. (0.40%). Company insiders that own Polarityte stock include Cameron J Hoyler, David B Seaburg, Denver Lough, Edward Winslow Swanson, Paul Elliot Mann, Peter A Cohen, Rainer M Erdtmann, Richard Hague and Steve Gorlin. View institutional ownership trends for Polarityte.

Which institutional investors are buying Polarityte stock?

PTE stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC, Advisor Group Holdings Inc., BlackRock Inc., State Street Corp, Geode Capital Management LLC, Levin Capital Strategies L.P., LWS Wealth Advisors Inc., and Capital Wealth Alliance LLC. Company insiders that have bought Polarityte stock in the last two years include Edward Winslow Swanson, Paul Elliot Mann, Peter A Cohen, and Rainer M Erdtmann. View insider buying and selling activity for Polarityte.

How do I buy shares of Polarityte?

Shares of PTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Polarityte's stock price today?

One share of PTE stock can currently be purchased for approximately $0.89.

How big of a company is Polarityte?

Polarityte has a market capitalization of $34.23 million and generates $5.65 million in revenue each year. The company earns $-92,490,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. Polarityte employs 153 workers across the globe.

What is Polarityte's official website?

The official website for Polarityte is www.polarityte.com.

How can I contact Polarityte?

Polarityte's mailing address is 123 NORTH WRIGHT BROTHERS DRIVE, SALT LAKE CITY UT, 84116. The company can be reached via phone at 385-237-2279 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff